Summary

OPERA I and OPERA II tested the safety and efficacy of ocrelizumab in patients with relapsing multiple sclerosis. Patients were randomized to either ocrelizumab or interferon beta-1a. At baseline, patient demographics and disease characteristics appear consistent with the majority of patients with the relapsing type of the disease.